Are health care providers who work with cancer drugs at an increased risk for toxic events? A systematic review and meta-analysis of the literature

Journal of Oncology Pharmacy Practice

Volumn 11, Issue 2, 2005, Pages 69-78

  Dranitsaris, George ^a   Johnston, Mary ^b   Poirier, Susan ^c   Schueller, Trudi ^d   Milliken, Debbie ^a   Green, Esther ^a   Zanke, Brent ^a  

^a CANCER CARE ONTARIO   (Canada)

^b Cancer Care Ontario   (Canada)

^c LONDON REGIONAL CANCER PROGRAM   (Canada)

^d DEPARTMENT OF RADIATION ONCOLOGY   (Canada)

Author keywords

Administration; Chemotherapy, health risks; Health care workers; Preparation; Workers

Indexed keywords

ANESTHETIC GAS; CHEMOSTERILANT; CYTOTOXIC AGENT; DRUG;

ACUTE TOXICITY; CANCER CENTER; CANCER RISK; COCHRANE LIBRARY; CONFIDENCE INTERVAL; CONGENITAL MALFORMATION; CONTROLLED STUDY; CORRELATION ANALYSIS; COST EFFECTIVENESS ANALYSIS; DECISION MAKING; DRUG EXPOSURE; ECTOPIC PREGNANCY; EMBASE; EPIDEMIOLOGICAL DATA; EVIDENCE BASED MEDICINE; GENITAL SYSTEM DISEASE; HEALTH CARE PERSONNEL; HEALTH CARE POLICY; HUMAN; MAJOR CLINICAL STUDY; MEDICAL LITERATURE; MEDLINE; OCCUPATIONAL EXPOSURE; OCCUPATIONAL HAZARD; PERSONNEL MANAGEMENT; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK REDUCTION; SPONTANEOUS ABORTION; STATISTICAL ANALYSIS; STATISTICAL MODEL; STILLBIRTH; SYSTEMATIC REVIEW;

ABORTION, SPONTANEOUS; ANTINEOPLASTIC AGENTS; FEMALE; FETAL DEATH; HEALTH PERSONNEL; HUMANS; MALE; NEOPLASMS; OCCUPATIONAL DISEASES; OCCUPATIONAL EXPOSURE; PREGNANCY; PREGNANCY, ECTOPIC; RISK FACTORS; RISK MANAGEMENT;

EID: 23644447249     PISSN: 10781552     EISSN: None     Source Type: Journal    
DOI: 10.1191/1078155205jp155oa     Document Type: Review

References (34)

1. Matesich SM, Shapiro CL. Second cancers after breast cancer treatment. Semin Oncol 2003; 30: 740-48.
2. Andre M, Mounier N, Leleu X, et al. Second cancers and late toxicities after treatment of aggressive non-Hodgkin lymphoma with the ACVBP reginien: a GELA cohort study on 2837 patients. Blood 2004; 103: 1222-28.
3. Travis LB, Gospodarowicz M, Curtis RE, et al. Lung cancer following chemotherapy and radiotherapy for Hodgkin's disease. J Natl Cancer Inst 2002; 94: 182-92.
4. Crump M, Tu D, Shepherd L, et al. Risk of acute leukemia following epirubicin-based adjuvant chemotherapy: a report from the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2003 Aug 15; 21: 3066-71.
5. Chronowski GM, Wilder RB, Levy LB, et al. Second malignancies after chemotherapy and radiotherapy for Hodgkin disease. Am J Clin Oncol 2004; 27: 73-80.
6. Sotaniemi EA, Sutinen S, Arranto AJ, et al. Liver damage in nurses handling cytostatic agents. Acta Med Scand 1983; 214: 181-89.
7. Levin LI, Holly EA, Seward JP. Bladder cancer in a 39-year-old female pharmacist. J Natl Cancer Inst 1993; 85: 1089-91.
8. Hemminki K, Kyyronen P, Lindbohm ML. Spontaneous abortions and malformations in the offspring of nurses exposed to anaesthetic gases, cytostatic drugs, and other potential hazards in hospitals, based on registered information of outcome. J Epidemiol Community Health 1985; 39: 141-47.
9. Peelen S, Roeveld N, Heederick D, et al. Toxic effects on reproduction in hospital personnel. Dutch Ministry of Social Affairs and Employment. 1999. [Translation from Dutch to English by Interverbum, Gotheberg, Sweden].
10. U.S. Department of Labor. Guidelines for cytotoxic (antineoplastic) drugs. Washington, DC: U.S. Occupational Health and Safety Administration, Office of Occupational Medicine, 1986; publication no. 8-1.1.
11. AMA Council of Scientific Affairs. Guidelines for handling parenteral antineoplastics. JAMA 1985; 253: 1590-92.
12. Connor T, Anderson R, Sessink PJM, et al. Surface contamination with antineoplastic agents in six cancer centres in Canada and the United States. Am J Health Syst Pharm 1999; 56: 1427-32.
13. Sessink PJ, Boer KA, Scheefhals AP, et al. Occupational exposure to antineoplastic agents at several departments in a hospital. Environmental contamination and excretion of cyclophosphamide and ifosfamide in urine of exposed workers. Int Arch Occup Environ Health 1992; 64: 105-12.
14. DerSimonian R, Laird N. Meta-analysis in clinical trials. Controlled Clin Trials 1986; 7: 177-88.
15. Thompson SG, Sharp SJ. Explaining heterogeneity in meta-analysis: a comparison of methods. Stat Med 1999; 18: 2693-708.
16. Sutton AJ, Abrams KR, Jones DR, et al. Methods for Meta-analysis in Medical Research. Chichester: John Wiley & Sons Ltd., 2000.
17. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta analyses. BMJ 2003; 327: 557-60.
18. Gunnarsdottir HK, Aspelund T, Karlsson T, Rafnsson V. Occupational risk factors for breast cancer among nurses. Int J Occup Environ Health 1997; 3: 254-258.
19. Skov T, Maarup B, Olsen J, et al. Leukaemia and reproductive outcome among nurses handling antineoplastic drugs. Br J Ind Med 1992; 49: 855-61.
20. Selevan SG, Lindbohm ML, Hornung RW, Hemminki K. A study of occupational exposure to antineoplastic drugs and fetal loss in nurses. N Engl J Med 1985; 313: 1173-78.
21. McAbee RR, Gallucci BJ, Checkoway H. Adverse reproductive outcomes and occupational exposures among nurses: an investigation of multiple hazardous exposures. AAOHN J 1993; 41: 110-19.
22. Stucker I, Caillard JF, Collin R, et al. Risk of spontaneous abortion among nurses handling antineoplastic drugs. Scand J Work Environ Health 1990; 16: 102-107.
23. Lorente C, Cordier S, Bergeret A, et al. Maternal occupational risk factors for oral clefts. Occupational Exposure and Congenital Malformation Working Group. Scand J Work Environ Health 2000; 26: 137-45.
24. Bouyer J, Saurel-Cubizolles MJ, Grenier C, et al. Ectopic pregnancy and occupational exposure of hospital personnel. Scand J Work Environ Health 1998; 24: 98-103.
25. Valanis B, Vollmer WM, Steele P. Occupational exposure to antineoplastic agents: self-reported miscarriages and stillbirths among nurses and pharmacists. J Occup Environ Med 1999; 41: 632-38.
26. Saurel-Cubizolles MJ, Job-Spira N, Estryn-Behar M. Ectopic pregnancy and occupational exposure to antineoplastic drugs. Lancet 1993; 341: 1169-71.
27. McDonald AD, McDonald JC, Armstrong B, et al. Congenital defects and work in pregnancy. Br J Ind Med 1988; 45: 581-88.
28. Valanis BG, Hertzberg V, Shortridge L. Antineoplastic drugs. Handle with care. AAOHN J 1987; 35: 487-92.
29. Valanis BG, Vollmer WM, Labuhn KT, Glass AG. Association of antineoplastic drug handling with acute adverse effects in pharmacy personnel. Am J Hosp Pharm 1993; 50: 455-62.
30. Valanis BG, Vollmer WM, Labuhn KT, Glass AG. Acute symptoms associated with antineoplastic drug handling among nurses. Cancer Nurs 1993; 16: 288-95.
31. Ropeik D, Slovic P. Risk communication: A neglected tool in protecting public health. Risk Perspective 2003: 11: 1-4.
32. Slovic P, Finucane ML, Peters E, MacGregor DG. Risk as analysis and risk as feelings: some thoughts about affect, reason, risk, and rationality. Risk Anal 2004; 24: 311-22.
33. Wadhera S, Miller WJ. Pregnancy outcomes. Health reports: Statistics Canada 1996; 8: 7-15.
34. National Institute for Occupational Safety and Health (NIOSH). Preventing Occupational Exposures to Antineoplastic and Other Hazardous Drugs in Health Care Settings. Retrieved September 2004, from http://www.cdc.gov/niosh.